**INTERPRETATION OF GENOMIC ASSAYS – FAQs**

What do all the different symbols and numbers one sees in a genomic report mean?

Consistency in nomenclature helps people with different training and experience and different laboratories to identify the same variant. Variants may be identified by alteration to protein (e.g. \( \text{BRAF} \) p.V600E), nucleotide (e.g. \( \text{BRCA1} \) c.5266dupC), or non-standard nomenclature (e.g. \( \text{TERT} \) C228T promoter mutations or \( \text{EML4/ALK} \) fusion transcripts). The genomic location and transcript IDs are often included as universal references for additional clarity. See below for examples.

I am not familiar with the variant identified in the report. Where can I go for additional information?

In addition to any information issued in an interpretation (see below for a generic example) there are many online resources that may be useful, including MyCancerGenome.org, TCGA, PubMed, GoogleScholar, FDA.gov, and ClinicalTrials.gov. Advanced users may find databases such as COSMIC, CiVIC, or cBioPortal useful. For additional assistance, please contact the laboratory or the molecular professional who issued the report.

Will the assay detect the ABC variant in gene XYZ?

Check the assay description - Is gene \( \text{XYZ} \) included on the panel? Is the region including the ABC mutation included on the panel? Does the assay detect this type of mutation (e.g., large indels or structural variants)? For additional assistance, please contact the laboratory or the molecular professional who issued the report.

The report says there are no variants in gene XYZ. Could the assay have missed anything?

Every assay has limitations in its ability to detect all types of variants. There is always a lower limit of detection; moreover, genomic assays do not necessarily identify every type of variant with equivalent sensitivity. An assay may perform well in identifying single-nucleotide variants (SNVs), less well in identifying insertions and deletions (indels), and may not be able to identify larger indels at all. Negative results must always be interpreted with caution.

What is the significance of the Variant Allele Frequency (VAF)?

The VAF is the frequency at which the variant is detected in a specimen. It is often used as a proxy for disease burden. However, the VAF is affected by many factors including the variance of the assay (often as high as +/-15%), sampling, assay design, and cytogenetic changes at the allele including amplification or loss of heterozygosity (LOH). The VAF should always be interpreted with caution. For additional assistance, please contact the laboratory or the molecular professional who issued the report.

**Example Interpretation:** \( \text{XYZ} \) p.ABC: A single base substitution was detected in the \( \text{XYZ} \) gene, resulting in a missense variant. \( \text{XYZ} \) functions as a [tumor suppressor/oncogene/other], regulating downstream cellular processes including ###. This variant occurs in the ### domain, altering the ability of the protein to ####, resulting in ####. The p.ABC variant confers a [better/worse] prognosis, and is a target for the US-FDA approved therapy, #######.

Methodology of the assay (the fine print) should include: Reference genome used (e.g. \( \text{hg19} \)); target gene list; regions of genes covered (e.g. entire coding region vs. hotspots); minimum mean depth of coverage; performance characteristics of the assay (lower limits of detection, maximum size of detectable indels, variance, etc.); contact information for the laboratory.

Prepared by the Association for Molecular Pathology Training and Education Committee

For more educational resources, see: www.amp.org/AMPEducation

*“Molecular In My Pocket” reference cards are educational resources created by the Association of Molecular Pathology (AMP) for laboratory and other health care professionals. The content does not constitute medical or legal advice, and is not intended for use in the diagnosis or treatment of individual conditions. See www.amp.org for the full “Limitations of Liability” statement.*

Revised 7/2021